Rybelsus 14 mg Tablet


Rybelsus® 14 mg is a once-daily oral GLP-1 receptor agonist containing semaglutide, used to improve blood sugar control in adults with type 2 diabetes mellitus. It is the highest available dose in the Rybelsus titration regimen and is intended for patients who require additional glycemic control beyond the 7 mg dose.

$450.00

Compare

Available Packages:

Overview:
Rybelsus® 14 mg is a once-daily oral GLP-1 receptor agonist containing semaglutide, used to improve blood sugar control in adults with type 2 diabetes mellitus. It is the highest available dose in the Rybelsus titration regimen and is intended for patients who require additional glycemic control beyond the 7 mg dose.

Key Details:

  • Active Ingredient: Semaglutide 14 mg

  • Form: Oral tablet

  • Therapeutic Class: GLP-1 receptor agonist

  • Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Intended Use:
Rybelsus 14 mg is typically prescribed after patients have tolerated and responded to the 7 mg dose for at least 30 days, and need further improvement in blood glucose levels. It may be used alone or in combination with other diabetes medications, except for other GLP-1 receptor agonists.

How It Works:
Semaglutide mimics the action of the naturally occurring GLP-1 hormone, promoting insulin secretion, reducing glucagon release, and slowing gastric emptying. These combined actions help reduce postprandial and fasting blood glucose levels.

Dosage & Administration:

  • Take one 14 mg tablet once daily, on an empty stomach

  • Use with up to 4 oz (120 mL) of plain water only

  • Wait at least 30 minutes before eating, drinking, or taking any other medications

Key Benefits:

  • Oral GLP-1 therapy—no injections required

  • Helps significantly reduce HbA1c levels

  • May contribute to weight loss in some patients

  • Convenient once-daily oral dosing

Safety Information:

  • Not for use in patients with type 1 diabetes or for treating diabetic ketoacidosis

  • Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2

  • Common side effects: nausea, vomiting, diarrhea, abdominal discomfort, and loss of appetite

  • Increased risk of hypoglycemia when used with insulin or sulfonylureas

Storage Instructions:
Store at room temperature: 20°C to 25°C (68°F to 77°F). Protect from moisture. Keep in original packaging until use.

Important Note:
Rybelsus 14 mg should only be used under the guidance and prescription of a licensed healthcare provider.

package

30 Tablet/S, 60 Tablet/S, 90 Tablet/S